Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx in Congestive Heart Failure and Angina
NCT05147766Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Feb 2022
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in heart failure (HF) and Angina Pectoris (AP), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Started Feb 2022; status: terminated.
02
Drugs
AlloRx
03
Conditions
heart failure (HF)Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT05147766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147766.